ObjectiveTo summarize the burden and epidemiological trends of global breast cancer and China’s breast cancer according to the 2018, 2020 and 2022 versions of the global cancer statistics report jointly prepared by the International Cancer Research Institute of the World Health Organization and the American Cancer Society. MethodThe data of global and Chinese breast cancer in the 2018, 2020, 2022 edition of the Global Cancer Statistical Report were analyzed. ResultsIn 2022, the global new breast cancer was estimated to be about 2.309 million, ranking the second. The crude incidence rate of breast cancer was 54.1 per 100 000, and the age standardized incidence rate (ASIR) was 46.8 per 100 000. In 2022, the global breast cancer death would be about 666 000, ranking the fourth, with the crude mortality rate of 11.3 per 100 000, age standardized mortality rate (ASMR) was 12.6 per 100 000. The incidence rate and mortality rate of breast cancer vary greatly between regions/countries, and were related to the human development index; the crude incidence rate was high in economically developed regions, and the crude mortality rate was relatively increasing, but the ASMR was low. In economically underdeveloped areas, the crude incidence rate was relatively low, and the crude mortality rate was relatively decreasing, but ASMR was high. In 2022, the number of breast cancer patients in China would be 357 000, ranking the fourth, with a crude incidence rate of 51.7 per 100 000 and an ASIR of 33.0 per 100 000. In 2022, there would be about 75 000 deaths from breast cancer in China, ranking the seventh, with a crude mortality rate of 10.9 per 100 000 and an ASMR of 6.1 per 100 000. From 2018 to 2022, the incidence rate and mortality rate of breast cancer in China show a downward trend. ConclusionsBoth the world and China are facing a severe burden of breast cancer, and breast cancer prevention and treatment has a long way to go.
ObjectiveTo analyze the burden and incidence of thyroid cancer in the world and in China based on the 2018, 2020 and 2022 editions of the Global Cancer Statistical Report jointly compiled by the World Health Organization (IARC) and the American Cancer Society. MethodsThe global cancer registry data of GLOBOCAN in 2018, 2020 and 2022 were compiled and analyzed, and the crude and age-standardized rates of thyroid cancer incidence in the world and China were extracted, and the incidence characteristics of thyroid cancer in the world and China were compared. ResultsIn 2022, the number of new thyroid cancers in the world was estimated to be about 821 000, ranking 7th among all cancers, with a crude incidence rate of 10.4 per 100 000. The number of new cases of thyroid cancer in China will be about 466 000, ranking third, with a crude incidence rate of 33.0 per 100 000. There are significant differences in the incidence of thyroid cancer among different genders: in 2022, the number of new cases of thyroid cancer in women is about three times that of men, and the crude incidence rate in women is significantly higher than that in men. From 2018 to 2022, the incidence of thyroid cancer increased year by year in the world and China. ConclusionsThe disease burden of thyroid cancer in China is still heavy and higher than the global level, and the prevention and treatment of thyroid cancer is still facing great challenges.